Breakthrough in Bladder Cancer: Personalizing Treatment with Blood Tests Could Save Lives – But Is It Fair for Everyone?
Imagine discovering a simple blood test that predicts if bladder cancer will return after surgery, guiding doctors to offer targeted therapy only to those who truly need it. This isn't science fiction; it's the promising reality from a recent study on muscle-invasive bladder cancer (MIBC). But here's where it gets intriguing: This approach challenges traditional staging methods, potentially sparing some patients from unnecessary treatments while ensuring others get the help they deserve. Dive in as we unpack the details, and we'll highlight why this might spark debate among experts and patients alike.
Exciting results from a detailed subgroup analysis of the IMvigor011 trial reveal that using adjuvant atezolizumab (sold under the brand name Tecentriq) leads to significant improvements in disease-free survival (DFS) and overall survival (OS) compared to a placebo, no matter the size of the tumor, the status of nearby lymph nodes, or whether the patient had received neoadjuvant chemotherapy (NAC) beforehand. This benefit holds true for patients whose blood showed circulating tumor DNA (ctDNA) – essentially, tiny fragments of cancer DNA floating in the bloodstream – detected through repeated testing. For newcomers to this topic, think of ctDNA as a sneak peek into hidden cancer activity; it's like a molecular detective that flags if cancer is lurking undetected, even after surgery.
These findings, presented at the 26th Annual Meeting of the Society of Urologic Oncology, underscore how ongoing ctDNA monitoring can steer the use of atezolizumab in MIBC. Intriguingly, higher rates of ctDNA positivity were seen in individuals with more advanced tumor stages or positive lymph node involvement at the time of cystectomy (the surgical removal of the bladder). However, the researchers pointed out that relying solely on surgical staging isn't enough to predict ctDNA results accurately. On a brighter note, patients who consistently tested negative for ctDNA post-surgery faced a low risk of cancer returning or death, regardless of their tumor stage, lymph node status, or prior NAC exposure.
And this is the part most people miss: It flips the script on risk assessment. As Juergen E. Gschwend, MD, PhD, a leading urology professor from the Technical University of Munich’s School of Medicine in Germany, explained during the presentation, these outcomes back the idea of using serial ctDNA tests after cystectomy to go beyond standard pathological staging. This helps pinpoint those with ctDNA-positive MIBC who would gain from adjuvant atezolizumab, while avoiding overtreatment for those who stay ctDNA-negative.
Key Insights from the IMvigor011 Subgroup Exploration
- Treatment with adjuvant atezolizumab markedly boosted DFS and OS over placebo in ctDNA-positive MIBC cases, with consistent results across various tumor stages, lymph node statuses, and histories of neoadjuvant chemotherapy.
- For those maintaining ctDNA negativity, DFS and OS remained impressively high after cystectomy, unaffected by tumor stage, lymph node involvement, or past NAC.
- In summary, these findings suggest that regular ctDNA testing can refine risk evaluation post-cystectomy, aiding in the precise selection of ctDNA-positive MIBC patients who stand to benefit from adjuvant atezolizumab.
What Earlier IMvigor011 Data Revealed About Atezolizumab's Role in ctDNA-Positive MIBC
Radical cystectomy, sometimes combined with neoadjuvant treatments, offers a chance at curing MIBC, yet outcomes vary widely among patients. This variability drives the urgent need to better spot those at elevated risk of recurrence. Growing evidence supports the use of ctDNA-based detection of minimal residual disease (MRD) – the tiny traces of cancer left behind – after cystectomy as a powerful prognostic tool. MRD, in simple terms, is like finding leftover crumbs after cleaning up a mess; it indicates if the cancer might regrow.
The IMvigor011 trial was crafted to assess atezolizumab's adjuvant use in ctDNA-positive MIBC through continuous ctDNA surveillance. Initial results, shared at the 2025 ESMO Congress and published in the New England Journal of Medicine, showed that at a median follow-up of 16.1 months, ctDNA-positive patients on atezolizumab (167 individuals) had a median DFS of 9.9 months (95% CI, 7.2-12.7) versus 4.8 months (95% CI, 4.1-8.3) for those on placebo (83 patients), as per investigator evaluations (HR, 0.64; 95% CI, 0.47-0.87; P = .0047). The DFS hazard ratio stood at 0.69 (95% CI, 0.48-0.91). For OS, the median was 32.8 months (95% CI, 27.7-NE) with atezolizumab compared to 21.1 months (95% CI, 14.7-NE) on placebo (HR, 0.59; 95% CI, 0.39-0.90; P = .0131).
Trial Design of IMvigor011: How It Was Set Up
IMvigor011 included MIBC patients who had undergone radical cystectomy between 6 and 24 weeks before screening, with confirmed urothelial cancer stages ranging from (y)pT2-T4aN0M0 to (y)pT0-T4aN+M0, showing no signs of disease progression on imaging. Previous NAC was allowed, and participants needed an ECOG performance status of 0 to 2 (a measure of how well patients can perform daily activities, with 0 being fully active).
After joining, patients received ctDNA tests every 6 weeks and imaging scans every 12 weeks for the first year post-cystectomy. If ctDNA came back negative initially, testing continued; those staying negative for up to a year received no treatment and just ongoing monitoring. But if any test turned positive without visible disease on scans, patients were randomized 2:1 to either 1680 mg of atezolizumab or placebo every 4 weeks for a year.
The main goal was investigator-assessed DFS, with OS as a crucial secondary outcome. Out of 761 enrolled during surveillance, 379 eventually tested ctDNA-positive, 377 remained persistently negative, and 5 had no results. Pathological staging at cystectomy varied: some had (y)pT2N0 (ctDNA-positive: 48; negative: 129, including pT2N0 subsets), others (y)pT3-4N0 (123 positive, 171 negative), (y)pT≤2N+ (66 positive, 45 negative), or (y)pT3–4N+ (141 positive, 30 negative). Positivity rates rose with stage: 20.5% for pT2N0, 33.0% for (y)pT2N0, 41.8% for (y)pT3-4N0, 59.5% for (y)pT≤2N+, and 82.5% for (y)pT3–4N+. Data was cut off on June 15, 2025, with a median follow-up from randomization of 16.1 months.
DFS and OS Variations by Tumor Stage, Nodal Status, and Prior NAC in ctDNA-Positive Patients
Tumor Stage
For those with earlier-stage (y)p≤T2 disease:
- Atezolizumab yielded a median DFS of 14.8 months (95% CI, 6.6-25.1) for 53 patients, versus 8.4 months (95% CI, 4.2-14.6) for 27 on placebo (unstratified HR, 0.56; 95% CI, 0.31-1.01).
- Twelve- and 24-month DFS rates were 54.9% and 36.2% with atezolizumab, compared to 37.1% and not evaluable (NE) on placebo.
- Median OS was NE (95% CI, 29.1-NE) for atezolizumab versus 27.4 months (95% CI, 20.1-NE) for placebo (unstratified HR, 0.77; 95% CI, 0.32-1.90).
- Twelve- and 24-month OS rates: 91.9% and 74.0% with atezolizumab, versus 91.8% and 60.6% on placebo.
In more advanced (y)pT3–4 cases:
- Median DFS was 8.3 months (95% CI, 6.5-10.6) for 114 on atezolizumab versus 4.2 months (95% CI, 3.0-6.3) for 56 on placebo (unstratified HR, 0.64; 95% CI, 0.45-0.92).
- Twelve- and 24-month DFS rates: 39.8% and 24.1% with atezolizumab, versus 25.7% and 18.4% on placebo.
- Median OS: 29.9 months (95% CI, 21.1-NE) for atezolizumab versus 13.1 months (95% CI, 10.5-NE) for placebo (unstratified HR, 0.58; 95% CI, 0.37-0.93).
- Twelve- and 24-month OS rates: 81.9% and 57.4% with atezolizumab, versus 58.3% and 40.0% on placebo.
Nodal Status
Among those without lymph node involvement ((y)pN0):
- Median DFS: 8.3 months (95% CI, 4.5-13.2) for 71 on atezolizumab versus 6.2 months (95% CI, 2.3-10.6) for 35 on placebo (unstratified HR, 0.74; 95% CI, 0.45-1.12).
- Twelve- and 24-month DFS rates: 42.5% and 25.2% with atezolizumab, versus 30.6% and 10.2% on placebo.
- Median OS: 29.9 months (95% CI, 21.1-NE) for atezolizumab versus 18.1 months (95% CI, 12.1-NE) for placebo (unstratified HR, 0.72; 95% CI, 0.38-1.39).
- Twelve- and 24-month OS rates: 81.2% and 55.4% with atezolizumab, versus 69.2% and 43.9% on placebo.
For those with positive lymph nodes ((y)pN+):
- Median DFS: 10.4 months (95% CI, 7.1-19.5) for 96 on atezolizumab versus 4.8 months (95% CI, 4.1-8.3) for 48 on placebo (unstratified HR, 0.58; 95% CI, 0.39-0.86).
- Twelve- and 24-month DFS rates: 46.4% and 30.0% with atezolizumab, versus 28.6% and 13.4% on placebo.
- Median OS: 34.4 months (95% CI, 29.1-NE) for atezolizumab versus 22.2 months (95% CI, 17.4-NE) for placebo (unstratified HR, 0.61; 95% CI, 0.36-1.05).
- Twelve- and 24-month OS rates: 87.8% and 67.8% with atezolizumab, versus 70.9% and 48.4% on placebo.
Prior NAC
In patients without prior NAC:
- Median DFS: 10.5 months (95% CI, 6.6-14.5) for 87 on atezolizumab versus 5.3 months (95% CI, 2.3-9.7) for 50 on placebo (unstratified HR, 0.66; 95% CI, 0.44-1.00).
- Twelve- and 24-month DFS rates: 45.1% and 28.1% with atezolizumab, versus 34.9% and 16.4% on placebo.
- Median OS: 35.9 months (95% CI, 24.4-NE) for atezolizumab versus 18.2 months (95% CI, 13.1-NE) for placebo (unstratified HR, 0.52; 95% CI, 0.31-0.89).
- Twelve- and 24-month OS rates: 89.0% and 65.5% with atezolizumab, versus 66.5% and 43.9% on placebo.
In those with prior NAC:
- Median DFS: 8.2 months (95% CI, 6.1-12.8) for 80 on atezolizumab versus 4.4 months (95% CI, 3.7-10.4) for 33 on placebo (unstratified HR, 0.59; 95% CI, 0.37-0.95).
- Twelve- and 24-month DFS rates: 44.5% and 28.1% with atezolizumab, versus 20.1% and 5.0% on placebo.
- Median OS: 30.8 months (95% CI, 22.0-NE) for atezolizumab versus NE (95% CI, 14.7-NE) for placebo (unstratified HR, 1.00; 95% CI, 0.50-1.99).
- Twelve- and 24-month OS rates: 80.5% and 69.9% with atezolizumab, versus 75.7% and 53.3% on placebo.
DFS and OS Results for Persistent ctDNA-Negative Patients by Tumor Stage, Nodal Status, and Prior NAC
When looking at tumor stage:
- In the (y)p≤T2 group (166 patients), 12- and 24-month DFS rates were 96.3% and 89.1%, with OS rates of 100% and 97.3%.
- In the (y)pT3–4 group (189 patients), DFS rates were 94.6% and 87.5%, and OS rates were 100% and 96.9%.
By nodal status:
- For (y)pN0 (285 patients), DFS rates stood at 96.4% and 89.3%, with OS rates of 100% and 96.7%.
- For (y)pN+ (72 patients), DFS rates were 91.5% and 84.5%, and OS rates were 100% and 98.4%.
Based on prior NAC:
- In patients without NAC (189 patients), DFS rates were 96.2% and 86.2%, with OS rates of 100% and 95.7%.
- For those with NAC (168 patients), DFS rates were 94.6% and 90.8%, and OS rates were 100% and 98.6%.
References
- Gschwend JE, Bellmunt J, Arslan C, et al. Circulating tumor DNA-guided adjuvant atezolizumab vs placebo in patients with muscle-invasive bladder cancer after radical cystectomy: exploratory subgroup analysis of the phase 3 IMvigor011 trial. Presented at: 26th Annual Meeting of the Society of Urologic Oncology. December 2-5, 2025; Phoenix, Arizona.
- Powles T, Kann AG, Castellano D, et al. ctDNA-guided adjuvant atezolizumab in muscle-invasive bladder cancer. N Engl J Med. Published online October 20, 2025. doi:10.1056/NEJMoa2511885
Newsletter
Stay up to date on the most recent and practice-changing oncology data
This study challenges the status quo by suggesting ctDNA testing could be a game-changer for MIBC treatment. But is it controversial? Critics might argue it could widen inequalities if access to such advanced blood tests isn't universal, or perhaps over-rely on technology over clinical judgment. What do you think – could this lead to better outcomes for all, or does it introduce new risks? Do you agree with prioritizing ctDNA-positive patients for therapy, or should everyone get a shot? Share your opinions in the comments below; we'd love to hear from oncologists, patients, and curious minds alike!
